학술논문
A randomized phase 3 study comparing once-daily elvitegravir to twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-Week Results
Document Type
Article
Author
Source
In: Journal of Acquired Immune Deficiency Syndromes . (Journal of Acquired Immune Deficiency Syndromes, In Press, 29 April 2013)
Subject
Language
English
ISSN
15254135